Condition: Pulmonary Arterial Hypertension · Right Heart Failure · Right Ventricular Dysfunction · Sponsor: University of Washington
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.
This description comes directly from the study's public registry record.
Laurie Hogl, RRT · 206.543.8334 · lalnaser@uw.edu
Nancy Liston, MS · 206.543.8334 · nmliston@uw.edu
Always discuss trial participation with your own doctor first.
| University of Washington Medical Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06053580